In the study by Skoulidis et al., metastatic adenocarcinoma NSCLC patients with KRAS mutation alone and co-mutation in STK11 were resistant to PD-1 inhibitors alone (ORR = 7.4% vs. 28.6%, p < 0.0001, mPFS 1.9 months vs. 2.7 months, p < 0.001 and mOS 6.4 months vs. 16 months, p = 0.0015, respectively) [28,29]. The gene discussed is STK11; the disease is non-small cell lung carcinoma.